Back to base pairs: What is the genetic risk for red bloodcell alloimmunization?

SCORE consortium

doi:10.1016/j.blre.2020.100794

Back to base pairs: What is the genetic risk for red bloodcell alloimmunization?

SCORE consortium

Research output: Contribution to journal › Review article › Academic › peer-review

7 Citations (Scopus)

Abstract

Red blood cell (RBC) alloimmunization is a serious complication of blood transfusions, challenging selection of compatible units for future transfusions. Genetic characteristics may be associated with the risk of RBC alloimmunization and may therefore serve to identify high-risk patients. The aim of this systematic review was to summarize the available evidence on genetic risk factors for RBC alloimmunization. Electronic databases were searched up to April 2020 for studies (Search terms included transfusion, alloimmunization and genetic). A total of 2581 alloimmunized cases and 26,558 controls were derived from 24 studies. The alleles that were most frequently studied and that demonstrated significant associations in a meta-analysis with alloimmunization to the Duffy^a antigen were HLA-DRB1*04 (Odds Ratio 7.80 (95%CI 4.57–13.33)), HLA-DRB1*15 (OR 3.76 (95%CI 2.14–6.59)), and HLA-DRB1*03 (OR 0.12 (95%CI 0.05–0.29)). Furthermore, significant associations with anti-K formation was found for the alleles HLA-DRB1*10 (OR 2.64 (95%CI 1.41–4.95)), HLA*DRB1*11 (OR 2.11, (95%CI 1.34–3.32)), and HLA-DRB1*13 (OR 1.71 (95%CI 1.26–2.33)). Overall, the available evidence was of moderate to low quality, hampering interpretation of reported results. There is an urgent need for high quality evidence on genetic risk factors for RBC alloimmunization.

Original language	English
Article number	100794
Journal	Blood Reviews
Volume	48
DOIs	https://doi.org/10.1016/j.blre.2020.100794
Publication status	Published - Jul 2021

Bibliographical note

Funding Information:
This research was supported by a grant from the Netherlands Ministry of Health (PPOC 2016-34).The authors acknowledge Ren? Spijker, medical information specialist at the medical library of the Amsterdam University Medical Center.

Funding Information:
This research was supported by a grant from the Netherlands Ministry of Health ( PPOC 2016-34 ).

Publisher Copyright:
© 2021 The Author(s)

Research programs

EMC MM-02-54-03

Access to Document

10.1016/j.blre.2020.100794

Cite this

@article{df140092fece4c6ca94c0b3c3b9b4997,

title = "Back to base pairs: What is the genetic risk for red bloodcell alloimmunization?",

abstract = "Red blood cell (RBC) alloimmunization is a serious complication of blood transfusions, challenging selection of compatible units for future transfusions. Genetic characteristics may be associated with the risk of RBC alloimmunization and may therefore serve to identify high-risk patients. The aim of this systematic review was to summarize the available evidence on genetic risk factors for RBC alloimmunization. Electronic databases were searched up to April 2020 for studies (Search terms included transfusion, alloimmunization and genetic). A total of 2581 alloimmunized cases and 26,558 controls were derived from 24 studies. The alleles that were most frequently studied and that demonstrated significant associations in a meta-analysis with alloimmunization to the Duffya antigen were HLA-DRB1*04 (Odds Ratio 7.80 (95%CI 4.57–13.33)), HLA-DRB1*15 (OR 3.76 (95%CI 2.14–6.59)), and HLA-DRB1*03 (OR 0.12 (95%CI 0.05–0.29)). Furthermore, significant associations with anti-K formation was found for the alleles HLA-DRB1*10 (OR 2.64 (95%CI 1.41–4.95)), HLA*DRB1*11 (OR 2.11, (95%CI 1.34–3.32)), and HLA-DRB1*13 (OR 1.71 (95%CI 1.26–2.33)). Overall, the available evidence was of moderate to low quality, hampering interpretation of reported results. There is an urgent need for high quality evidence on genetic risk factors for RBC alloimmunization.",

author = "Gerritsma, {J. J.} and I. Oomen and {SCORE consortium} and S. Meinderts and {van der Schoot}, {C. E.} and Biemond, {B. J.} and {van der Bom}, {J. G.} and K. Fijnvandraat and {van Beers}, {E. J.} and M. Beijlevelt and Brons, {P. P.T.} and Cnossen, {M. H.} and L. Dovern and H. Heijboer and F. Hofstede and Kerkhoffs, {J. L.H.} and E. Nur and C. Ootjers and {de Pagter}, {P. J.} and Rijneveld, {A. W.} and Schols, {S. E.M.} and Smiers, {F. J.} and Suiker, {M. H.} and Teuben, {S. A.M.C.} and {van Tuijn}, {C. F.J.} and {van Vliet}, I. and E. Zwagemaker",

note = "Funding Information: This research was supported by a grant from the Netherlands Ministry of Health (PPOC 2016-34).The authors acknowledge Ren? Spijker, medical information specialist at the medical library of the Amsterdam University Medical Center. Funding Information: This research was supported by a grant from the Netherlands Ministry of Health ( PPOC 2016-34 ). Publisher Copyright: {\textcopyright} 2021 The Author(s)",

year = "2021",

month = jul,

doi = "10.1016/j.blre.2020.100794",

language = "English",

volume = "48",

journal = "Blood Reviews",

issn = "0268-960X",

publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - Back to base pairs

T2 - What is the genetic risk for red bloodcell alloimmunization?

AU - Gerritsma, J. J.

AU - Oomen, I.

AU - SCORE consortium

AU - Meinderts, S.

AU - van der Schoot, C. E.

AU - Biemond, B. J.

AU - van der Bom, J. G.

AU - Fijnvandraat, K.

AU - van Beers, E. J.

AU - Beijlevelt, M.

AU - Brons, P. P.T.

AU - Cnossen, M. H.

AU - Dovern, L.

AU - Heijboer, H.

AU - Hofstede, F.

AU - Kerkhoffs, J. L.H.

AU - Nur, E.

AU - Ootjers, C.

AU - de Pagter, P. J.

AU - Rijneveld, A. W.

AU - Schols, S. E.M.

AU - Smiers, F. J.

AU - Suiker, M. H.

AU - Teuben, S. A.M.C.

AU - van Tuijn, C. F.J.

AU - van Vliet, I.

AU - Zwagemaker, E.

N1 - Funding Information: This research was supported by a grant from the Netherlands Ministry of Health (PPOC 2016-34).The authors acknowledge Ren? Spijker, medical information specialist at the medical library of the Amsterdam University Medical Center. Funding Information: This research was supported by a grant from the Netherlands Ministry of Health ( PPOC 2016-34 ). Publisher Copyright: © 2021 The Author(s)

PY - 2021/7

Y1 - 2021/7

N2 - Red blood cell (RBC) alloimmunization is a serious complication of blood transfusions, challenging selection of compatible units for future transfusions. Genetic characteristics may be associated with the risk of RBC alloimmunization and may therefore serve to identify high-risk patients. The aim of this systematic review was to summarize the available evidence on genetic risk factors for RBC alloimmunization. Electronic databases were searched up to April 2020 for studies (Search terms included transfusion, alloimmunization and genetic). A total of 2581 alloimmunized cases and 26,558 controls were derived from 24 studies. The alleles that were most frequently studied and that demonstrated significant associations in a meta-analysis with alloimmunization to the Duffya antigen were HLA-DRB1*04 (Odds Ratio 7.80 (95%CI 4.57–13.33)), HLA-DRB1*15 (OR 3.76 (95%CI 2.14–6.59)), and HLA-DRB1*03 (OR 0.12 (95%CI 0.05–0.29)). Furthermore, significant associations with anti-K formation was found for the alleles HLA-DRB1*10 (OR 2.64 (95%CI 1.41–4.95)), HLA*DRB1*11 (OR 2.11, (95%CI 1.34–3.32)), and HLA-DRB1*13 (OR 1.71 (95%CI 1.26–2.33)). Overall, the available evidence was of moderate to low quality, hampering interpretation of reported results. There is an urgent need for high quality evidence on genetic risk factors for RBC alloimmunization.

AB - Red blood cell (RBC) alloimmunization is a serious complication of blood transfusions, challenging selection of compatible units for future transfusions. Genetic characteristics may be associated with the risk of RBC alloimmunization and may therefore serve to identify high-risk patients. The aim of this systematic review was to summarize the available evidence on genetic risk factors for RBC alloimmunization. Electronic databases were searched up to April 2020 for studies (Search terms included transfusion, alloimmunization and genetic). A total of 2581 alloimmunized cases and 26,558 controls were derived from 24 studies. The alleles that were most frequently studied and that demonstrated significant associations in a meta-analysis with alloimmunization to the Duffya antigen were HLA-DRB1*04 (Odds Ratio 7.80 (95%CI 4.57–13.33)), HLA-DRB1*15 (OR 3.76 (95%CI 2.14–6.59)), and HLA-DRB1*03 (OR 0.12 (95%CI 0.05–0.29)). Furthermore, significant associations with anti-K formation was found for the alleles HLA-DRB1*10 (OR 2.64 (95%CI 1.41–4.95)), HLA*DRB1*11 (OR 2.11, (95%CI 1.34–3.32)), and HLA-DRB1*13 (OR 1.71 (95%CI 1.26–2.33)). Overall, the available evidence was of moderate to low quality, hampering interpretation of reported results. There is an urgent need for high quality evidence on genetic risk factors for RBC alloimmunization.

UR - http://www.scopus.com/inward/record.url?scp=85107117967&partnerID=8YFLogxK

U2 - 10.1016/j.blre.2020.100794

DO - 10.1016/j.blre.2020.100794

M3 - Review article

C2 - 33451870

AN - SCOPUS:85107117967

SN - 0268-960X

VL - 48

JO - Blood Reviews

JF - Blood Reviews

M1 - 100794

ER -

Back to base pairs: What is the genetic risk for red bloodcell alloimmunization?

Abstract

Bibliographical note

Research programs

Access to Document

Other files and links

Fingerprint

Cite this